Alternating Sunitinib and Everolimus Is Not Efficacious As First-Line Therapy for aRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
EVERSUN: A Phase 2 Trial of Alternating Sunitinib and Everolimus as First Line Therapy for Advanced Renal Cell Carcinoma
Ann. Oncol 2015 Feb 20;[EPub Ahead of Print], ID Davis, A Long, S Yip, D Espinoza, JF Thompson, G Kichenadasse, M Harrison, RM Lowenthal, N Pavlakis, A Azad, G Kannourakis, C Steer, D Goldstein, J Shapiro, R Harvie, L Jovanovic, AL Hudson, CC Nelson, MR Stockler, A MartinRenal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.